| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/05/2004 | US20040022753 External application for enhancing the skin permeability of the active components therein |
| 02/05/2004 | US20040022741 Topical steroid spray |
| 02/05/2004 | US20040022740 Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| 02/05/2004 | US20040022739 Nasal spray formulation and method |
| 02/05/2004 | US20040022738 Administering intranasally a formulation comprised of the estrogenic compound and androgenic compound complexed with a cyclodextrin, for therapy of benign gynecological disorders, or for hormone replacement, for contraception |
| 02/05/2004 | US20040022734 For therapy of cancer, of fluorescent imaging and optoelectronics |
| 02/05/2004 | US20040021089 Device and method for photoactivation |
| 02/05/2004 | DE19924951B4 Verwendung von Desoxypeganin zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer Use of deoxypeganine for the prophylaxis or treatment of poisoning by organophosphorus cholinesterase inhibitors |
| 02/05/2004 | DE10234525A1 New compositions, useful as male contraceptives, comprise synergistic active agent combination of androgenic 11beta-halo-steroid and gestagenic 14 alpha, 17alpha-ethylene-estratrienone derivative |
| 02/05/2004 | DE10234522A1 Treating elevated sympathic activity, e.g. stress-induced hypertension, using noradrenaline transporter inhibitors such as sibutramine |
| 02/05/2004 | DE10233738A1 Stable suspensions of carotenoids, retinoids and/or unsaturated fatty acids, useful as additives in food, feed, pharmaceutical or cosmetic preparations, containing insoluble ascorbate salt particles as antioxidant |
| 02/05/2004 | DE10233737A1 Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen Use of modulators of signal transduction via the Fyn protein kinase for the treatment of tumor diseases |
| 02/05/2004 | DE10233632A1 Formulierungen von Phenylalanin-Derivaten Formulations of phenylalanine derivatives |
| 02/05/2004 | DE10232595A1 Lichtschutzmittel Light stabilizers |
| 02/05/2004 | DE10232571A1 4-Aminosubstituierte Pyrimidinderivate 4-Amino-substituted pyrimidine derivatives |
| 02/05/2004 | DE10232094A1 5-Thiaepothilone und 15-disubstituierte Epothilone 5-Thiaepothilone and 15-disubstituted epothilones |
| 02/05/2004 | DE10232079A1 Product for transporting macrocyclic lactone, especially bryostatin type antitumor agent, to site of action, obtained by mixing lactone with lyotropic cholesteric meso-phase in solution |
| 02/05/2004 | DE10231370A1 Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Thiophenglycosidderivate new, processes for their preparation, pharmaceutical compositions containing them and their use |
| 02/05/2004 | DE10230917A1 Fredericamycin-Derivate Fredericamycin derivatives |
| 02/05/2004 | DE10229456A1 Treatment of skin tumors and warts, by local application of preparations containing dopamine receptor agonists, especially bromocriptine |
| 02/05/2004 | DE10221831A1 Treatment of non-pathogen induced skin diseases, e.g. chronic eczema, neurodermatitis, psoriasis, urticaria or burns, by blockade of the 5HT-3 receptor, e.g. using tropisetron |
| 02/05/2004 | DE10220972A1 Side-effect free treatment of depression, by administration of S-(-)-lipoic acid or its salt at specific dosage |
| 02/05/2004 | DE10129927B4 Arzneimittel, enthaltend Derivate von Tetrahydrochinolin A medicament containing tetrahydroquinoline derivatives of |
| 02/05/2004 | CA2533587A1 Compounds active in sphingosine 1-phosphate signaling |
| 02/05/2004 | CA2529857A1 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| 02/05/2004 | CA2518732A1 Assays and methods based on microcompetition with a foreign polynucleotide |
| 02/05/2004 | CA2495167A1 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 02/05/2004 | CA2494668A1 Chemical compounds |
| 02/05/2004 | CA2494532A1 Total synthesis of myriaporones |
| 02/05/2004 | CA2494449A1 Ophtalmic compositions |
| 02/05/2004 | CA2494367A1 Methods for improvement of lung function using tgf-.beta. inhibitors |
| 02/05/2004 | CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | CA2494262A1 Polymorphisms for predicting disease and treatment outcome |
| 02/05/2004 | CA2494233A1 Formulations and dosage forms for controlled delivery of topiramate |
| 02/05/2004 | CA2494109A1 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 02/05/2004 | CA2494102A1 Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
| 02/05/2004 | CA2494069A1 Pellicle-resistant gelatin capsule |
| 02/05/2004 | CA2494038A1 Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure |
| 02/05/2004 | CA2493980A1 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | CA2493949A1 Modified small interfering rna molecules and methods of use |
| 02/05/2004 | CA2493913A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | CA2493878A1 Parenteral formulations containing a rapamycin hydroxyester |
| 02/05/2004 | CA2493790A1 Food improving blood flow |
| 02/05/2004 | CA2493782A1 Immunogenic compositions and diagnostic and therapeutic uses thereof |
| 02/05/2004 | CA2493761A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | CA2493755A1 Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications |
| 02/05/2004 | CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | CA2493701A1 Isothiazole derivatives useful as anticancer agents |
| 02/05/2004 | CA2493671A1 Lipophilic electrophoretic probes |
| 02/05/2004 | CA2493639A1 Persulfated oligosaccharide acting on selectins and chemokine |
| 02/05/2004 | CA2493629A1 Pramipexole once-daily dosage form |
| 02/05/2004 | CA2493584A1 Inhibition of stearoyl-coa desaturase 1 (scd1) increases insulin sensitivity and treats diabetes |
| 02/05/2004 | CA2493581A1 Ophthalmologic irrigation solutions and method |
| 02/05/2004 | CA2493207A1 Composition containing an androgenous 11.beta.-halogen steroid and a progestational hormone, and male contraceptive based on said composition |
| 02/05/2004 | CA2493179A1 Sustained-release tablet composition comprising a dopamine receptor agonist |
| 02/05/2004 | CA2493158A1 Preparation of 1h-imidazo [4,5-c] quinolin-4-amines via novel 1h-imidazo [4,5-c] quinolin-4-cyano and 1h-imidazo [4,5-c] quinolin-4-carboxamide intermediates |
| 02/05/2004 | CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | CA2493128A1 Crystalline .beta.2 adrenergic receptor agonist |
| 02/05/2004 | CA2493082A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
| 02/05/2004 | CA2493078A1 Medicament dispenser |
| 02/05/2004 | CA2493076A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 02/05/2004 | CA2493074A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 02/05/2004 | CA2492833A1 Use of modulators of the signal transduction path using the protein kinase fyn for the treatment of tumorous diseases |
| 02/05/2004 | CA2492607A1 Anti-viral 7-deaza d-nucleosides and uses thereof |
| 02/05/2004 | CA2492542A1 Oligodendrocyte production from multipotent neural stem cells |
| 02/05/2004 | CA2492463A1 Regulated aptamer therapeutics |
| 02/05/2004 | CA2492424A1 Sustained-release tablet comprising reboxetine |
| 02/05/2004 | CA2492210A1 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 02/05/2004 | CA2491733A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | CA2491078A1 Percutaneous and perungual delivery system |
| 02/05/2004 | CA2489165A1 Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands |
| 02/05/2004 | CA2488860A1 Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
| 02/05/2004 | CA2486714A1 Compositions for penis enlargement |
| 02/05/2004 | CA2401567A1 Methods of preventing the inhibition of apoptosis and treating inflammatory conditions |
| 02/04/2004 | EP1386934A1 Diagnostic agents for pancreatic exocrine function |
| 02/04/2004 | EP1386933A1 Cytokine antagonists and agonists |
| 02/04/2004 | EP1386922A2 Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| 02/04/2004 | EP1386921A1 Intermediates |
| 02/04/2004 | EP1386919A1 Remedies |
| 02/04/2004 | EP1386917A1 Intermediates |
| 02/04/2004 | EP1386914A1 Halogenated quinoline derivatives and ectoparasite controllers |
| 02/04/2004 | EP1386913A1 Pyrrole derivative |
| 02/04/2004 | EP1386912A1 Cyclic amidine derivative |
| 02/04/2004 | EP1386909A1 Cyclopropane amines |
| 02/04/2004 | EP1386908A1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 02/04/2004 | EP1386905A1 Stable solution of reduced coenzyme q |
| 02/04/2004 | EP1386624A1 Coated vascular devices |
| 02/04/2004 | EP1386616A1 Antibordetella vaccine |
| 02/04/2004 | EP1386615A1 EG-VEGF/Prokineticin 2 receptor antagonists |
| 02/04/2004 | EP1386613A1 Compositions for preparing external carbon dioxide agents |
| 02/04/2004 | EP1386612A1 Drugs fo rpromoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid |
| 02/04/2004 | EP1386611A1 Medicines and medicinal kits |
| 02/04/2004 | EP1386610A1 Medicament containing 2-HETE or 11,12-EET |
| 02/04/2004 | EP1386609A1 Adenosine A1 receptor antagonist containing composition and method for restoring diuretic and renal function |
| 02/04/2004 | EP1386608A1 Remedial agent for glomerular disease |
| 02/04/2004 | EP1386606A1 Stable high− concentration injection containing pyrazolone derivative |
| 02/04/2004 | EP1386605A1 Improved transdermal delivery system for the administration of rotigotine |
| 02/04/2004 | EP1386604A1 Improved transdermal delivery system |
| 02/04/2004 | EP1386543A1 New bacterial strain and the use thereof |
| 02/04/2004 | EP1386279A2 Method for inhibiting metap2 |